ArticleMaterials today. Bio2026
Sialic acid-guided spatiotemporal hydrogel therapy for liver cancer.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficient delivery of plant-derived polyphenolic drugs to tumor sites in hepatocellular carcinoma (HCC) is challenging due to their rapid metabolism and the limited tumor-targeting capacity of current therapeutic strategies. To overcome these limitations, we developed a pH-responsive hydrogel-based drug delivery system (PA-CB) composed of a chitosan backbone functionalized with boronobenzoic acid (CB) and crosslinked with protocatechualdehyde (PA). Within this scaffold, protocatechuic acid (PCA) was incorporated as a model therapeutic agent to demonstrate the platform's ability to achieve controlled, pH-responsive release and to impart anticancer, anti-inflammatory, and antifibrotic effects through the action of the drug. The hydrogel, stabilized via boronate ester and Schiff-base linkages, maintained integrity under physiological conditions while enabling drug markedly enhanced anticancer efficacy in vitro compared to free PCA, including a near-complete reduction of HepG2 cell viability, migration, and colony formation, along with increased apoptosis. This enhanced antitumor efficacy was due to CB-mediated recognition of sialic acid residues on HCC cells, which facilitated tumor-selective accumulation and sustained drug release. Intraperitoneal administration of the hydrogel in an HCC mouse model significantly reduced tumor burden, hepatic inflammation, and fibrosis, while improving liver function markers. Histological assessments confirmed alleviation of liver injury, and quantitative polymerase chain reaction analyses revealed decreased expression of proinflammatory cytokines. Collectively, these results highlight this hydrogel platform as a robust strategy to stabilize phenolic drugs, achieve tumor-targeted delivery, and enable controlled release. These findings highlight its potential as an advanced therapeutic approach for HCC and a versatile framework applicable to other polyphenolic agents in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.